{"id":2386,"date":"2025-01-10T16:42:40","date_gmt":"2025-01-10T13:42:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2386"},"modified":"2025-11-03T20:30:56","modified_gmt":"2025-11-03T17:30:56","slug":"plans-for-dyne-101-in-dm1-and-dyne-251-in-dmd-are-announced-by-dyne-therapeutics","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/plans-for-dyne-101-in-dm1-and-dyne-251-in-dmd-are-announced-by-dyne-therapeutics\/","title":{"rendered":"Planos para DYNE-101 em DM1 e DYNE-251 em DMD s\u00e3o anunciados pela Dyne Therapeutics"},"content":{"rendered":"<p class=\"wp-block-paragraph\">A Dyne Therapeutics anunciou dados cl\u00ednicos positivos para suas terapias DYNE-101 e DYNE-251 durante um evento para investidores em 10 de janeiro de 2025. O DYNE-101 para distrofia miot\u00f4nica tipo 1 (DM1) demonstrou corre\u00e7\u00e3o de splicing significativa e melhorias funcionais, levando a Dyne a planejar uma coorte global de expans\u00e3o de registro do estudo ACHIEVE com uma dose de registro de 6,8 mg\/kg Q8W e uma poss\u00edvel submiss\u00e3o de aprova\u00e7\u00e3o acelerada nos EUA no primeiro semestre de 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Enquanto isso, o DYNE-251, visando a distrofia muscular de Duchenne (DMD), tamb\u00e9m est\u00e1 buscando a Aprova\u00e7\u00e3o Acelerada dos EUA com base na distrofina como um desfecho substituto, com dados esperados para o final de 2025 para dar suporte a uma submiss\u00e3o no in\u00edcio de 2026. Ambos os programas mostram-se promissores na transforma\u00e7\u00e3o de paradigmas de tratamento para essas doen\u00e7as gen\u00e9ticas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ler mais<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/pt\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ensaios cl\u00ednicos para distrofia muscular de Duchenne (lista de todas as pesquisas)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy type 1 (DM1) demonstrated significant splicing correction and functional improvements, leading Dyne to plan a global Registrational Expansion Cohort of the ACHIEVE trial with a registrational dose of 6.8 mg\/kg Q8W [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2388,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[118,66,143,144,145],"class_list":["post-2386","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-duchenne","tag-duchenne-muscular-dystrophy","tag-dyne","tag-dyne-101","tag-dyne-251"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/2386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=2386"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/2386\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/2388"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=2386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=2386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=2386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}